Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1656 participants.

Also called NCT05491200

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,656 participants (planned count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as a collaborator
Registry
  • NCT NCT05491200
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium, Czechia, Germany, Italy, Netherlands, Serbia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05491200. Randomized; no masking; primary purpose treatment. Start 2022-07-22 (actual); primary completion 2027-08-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients
Condition
ST Elevated Myocardial Infarction
Condition
Dual Antiplatelet Therapy
Intervention (Drug)
Prasugrel based short DAPT
Intervention (Drug)
Prasugrel based standard DAPT
Intervention (Device)
OCT guided revascularization
Intervention (Device)
Angio guided revascularization
Lead sponsor
Research Maatschap Cardiologen Rotterdam Zuid (class: other)
Collaborator
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct05491200
Content hash
467662d76502ba88dda5205090668e769fe3957449216c1dee2af44732ea0454